Vimarsana
Biggest News Aggregation in the World

Page 29 - Registration Statements News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Registration Statements. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Registration Statements Today - Breaking & Trending Today

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron - Vimarsana News

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany’s business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (

CreditRiskMonitor.com, Inc.: CreditRiskMonitor Announces 2022 Results - Vimarsana News

CreditRiskMonitor.com, Inc.: CreditRiskMonitor Announces 2022 Results

VALLEY COTTAGE, NY / ACCESSWIRE / March 24, 2023 / CreditRiskMonitor (OTCQX:CRMZ) reported that operating revenues of $18 million, an increase of approximately $1 million or 5%, for the year ended December

CreditRiskMonitor Announces 2022 Results - Vimarsana News

CreditRiskMonitor Announces 2022 Results

CreditRiskMonitor Announces 2022 Results

GEE Group Inc.: GEE Group Announces Results for the Fiscal 2023 First Quarter - Vimarsana News

GEE Group Inc.: GEE Group Announces Results for the Fiscal 2023 First Quarter

JACKSONVILLE, FL / ACCESSWIRE / February 14, 2023 / GEE Group Inc. (NYSE American:JOB) together with its subsidiaries (collectively referred to as the "Company", "GEE Group", "us", "our", or "we"), a provider

Purple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results - Vimarsana News

Purple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple